journal
MENU ▼
Read by QxMD icon Read
search

Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research

journal
https://www.readbyqxmd.com/read/29753361/mothers-preferences-and-willingness-to-pay-for-human-papillomavirus-vaccination-for-their-daughters-a-discrete-choice-experiment-in-hong-kong
#1
Carlos K H Wong, Kenneth K C Man, Patrick Ip, Mike Kwan, Sarah M McGhee
OBJECTIVES: To determine the preference of mothers in Hong Kong and their willingness to pay (WTP) for human papillomavirus (HPV) vaccination for their daughters. METHOD: A discrete choice experiment survey with a two-alternative study design was developed. Data were collected from pediatric specialist outpatient clinics from 482 mothers with daughters aged between 8 and 17 years. Preferences of the four attributes of HPV vaccines (protection against cervical cancer, protection duration, side effects, and out-of-pocket costs) were evaluated...
May 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29753360/prediction-of-health-utility-scores-in-patients-with-chronic-hepatitis-c-using-the-chronic-liver-disease-questionnaire-hepatitis-c-version-cldq-hcv
#2
Maria Stepanova, Issah Younossi, Andrei Racila, Zobair M Younossi
BACKGROUND: Preference-based health utilities are used in economic analyses of disease burden and health care interventions. When specifically designed instruments cannot be applied, mapping algorithms for non-preference-based instruments can be used for prediction of health utility scores. OBJECTIVES: To develop a mapping algorithm for the Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV), the hepatitis C virus-specific quality-of-life instrument...
May 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29753359/challenges-in-valuing-temporary-health-states-for-economic-evaluation-a-review-of-empirical-applications-of-the-chained-time-trade-off-method
#3
REVIEW
Julija Stoniute, David John Mott, Jing Shen
BACKGROUND: The time trade-off (TTO) technique is commonly used to elicit health state utilities. Nevertheless, when the health states being valued are temporary, the TTO approach may be unsuitable. A variant of TTO- chained TTO-has been suggested to be used when the health states are temporary, but little research has been done on how chained TTO should be conducted. OBJECTIVES: To systematically review the use of chained TTO in valuing temporary health states...
May 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29753358/handling-data-quality-issues-to-estimate-the-spanish-eq-5d-5l-value-set-using-a-hybrid-interval-regression-approach
#4
Juan M Ramos-Goñi, Benjamin M Craig, Mark Oppe, Yolanda Ramallo-Fariña, Jose Luis Pinto-Prades, Nan Luo, Oliver Rivero-Arias
BACKGROUND: The Spanish five-level EuroQol five-dimensional questionnaire (EQ-5D-5L) valuation study was the first to use the EuroQol Valuation Technology protocol, including composite time trade-off (C-TTO) and discrete choice experiments (DCE). In this study, its investigators noticed that some interviewers did not fully explain the C-TTO task to respondents. Evidence from a follow-up study in 2014 confirmed that when interviewers followed the protocol, the distribution of C-TTO responses widened...
May 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29753357/personal-income-before-and-after-diagnosis-of-multiple-sclerosis
#5
Erik Landfeldt, Anna Castelo-Branco, Axel Svedbom, Emil Löfroth, Andrius Kavaliunas, Jan Hillert
BACKGROUND: Multiple sclerosis (MS) is associated with serious morbidity and labor force absenteeism, but little is known of the long-term impact of the disease on personal income. OBJECTIVES: To assess long-term consequences of MS on personal salary and disposable income. METHODS: Patients with MS in Sweden were identified in a nationwide, disease-specific register and matched with general population controls. We assessed mean annual personal gross salary and disposable income each year before and after index (i...
May 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29753356/measurement-equivalence-of-patient-reported-outcome-measure-response-scale-types-collected-using-bring-your-own-device-compared-to-paper-and-a-provisioned-device-results-of-a-randomized-equivalence-trial
#6
Bill Byrom, Helen Doll, Willie Muehlhausen, Emuella Flood, Cater Cassedy, Bryan McDowell, Jeremy Sohn, Kyle Hogan, Ryan Belmont, Barbara Skerritt, Marie McCarthy
OBJECTIVES: The aim of this study was to assess the measurement equivalence of individual response scale types by using a patient reported outcome measure (PROM) collected on paper and migrated into electronic format for use on the subject's own mobile device (BYOD) and on a provisioned device (site device). METHODS: Subjects suffering from chronic health conditions causing daily pain or discomfort were invited to participate in this single-site, single visit, three-way crossover study...
May 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29753355/setting-the-boundaries-for-economic-evaluation-investigating-time-horizon-and-family-effects-in-the-case-of-postnatal-depression
#7
Jemimah Ride
OBJECTIVES: This study investigates the impact of varying the boundaries of economic evaluation: time horizon and inclusion of family effects. The context is postnatal mental health, where although advocates for investment often include longer-term and family problems in describing the burden of postnatal depression, economic evaluations are usually limited to mothers' effects with a relatively short time horizon. This discrepancy may lead to suboptimal allocation of healthcare resources...
May 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29753354/the-development-of-the-guide-to-economic-analysis-and-research-gear-online-resource-for-low-and-middle-income-countries-health-economics-practitioners-a-commentary
#8
Chiaki Urai Adeagbo, Waranya Rattanavipapong, Lorna Guinness, Yot Teerawattananon
Public health authorities around the world are increasingly using economic evaluation to set priorities and inform decision making in health policy, especially in the development of health benefit packages. Nevertheless, researchers in low- and middle-income countries (LMICs) encounter many barriers when conducting economic evaluations. In 2015, the Health Intervention and Technology Assessment Program identified key technical and context-specific challenges faced in conducting and using health economic evaluations in LMICs...
May 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29753353/cost-effectiveness-of-a-technology-facilitated-depression-care-management-adoption-model-in-safety-net-primary-care-patients-with-type-2-diabetes
#9
Joel W Hay, Pey-Jiuan Lee, Haomiao Jin, Jeffrey J Guterman, Sandra Gross-Schulman, Kathleen Ell, Shinyi Wu
BACKGROUND: The Diabetes-Depression Care-Management Adoption Trial is a translational study of safety-net primary care predominantly Hispanic/Latino patients with type 2 diabetes in collaboration with the Los Angeles County Department of Health Services. OBJECTIVES: To evaluate the cost-effectiveness of an information and communication technology (ICT)-facilitated depression care management program. METHODS: Cost-effectiveness of the ICT-facilitated care (TC) delivery model was evaluated relative to a usual care (UC) and a supported care (SC) model...
May 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29753352/patient-access-to-medicines-for-rare-diseases-in-european-countries
#10
Andreja Detiček, Igor Locatelli, Mitja Kos
BACKGROUND: The number of authorized orphan and non-orphan medicines for rare diseases has increased in Europe. Patient access to these medicines is affected by high costs, weak efficacy/safety evidence, and societal value. European health care systems must determine whether paying for expensive treatments for only a few patients is sustainable. OBJECTIVES: This study aimed to evaluate patient access to orphan and non-orphan medicines for rare diseases in 22 European countries during 2005 to 2014...
May 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29753351/evaluating-and-valuing-drugs-for-rare-conditions-no-easy-answers
#11
Daniel A Ollendorf, Richard H Chapman, Steven D Pearson
We find ourselves in an era of unprecedented growth in the development and use of so-called "orphan" drugs to treat rare diseases, which are poised to represent more than one-fifth of pharmaceutical expenditures by 2022. This widespread use has been facilitated by legislative and regulatory incentives in both the United States and abroad, yet US payers and health systems have not yet made a concerted effort to understand whether and how rare diseases require special considerations on their part and how to adapt traditional methods of health technology assessment and economic evaluation to accommodate these situations...
May 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29753350/societal-preferences-for-funding-orphan-drugs-in-the-united-kingdom-an-application-of-person-trade-off-and-discrete-choice-experiment-methods
#12
Siobhan M Bourke, Catrin O Plumpton, Dyfrig A Hughes
BACKGROUND: It is unclear whether UK National Health Service (NHS) policies for orphan drugs, which permit funding of non-cost-effective treatments, reflect societal preferences. METHODS: We conducted person trade-off (PTO) and discrete choice experiment (DCE) among 3950 adults selected to be representative of the UK general population. Experimental design was informed by surveys of patients affected by rare diseases, their caregivers, health care staff, and policymakers...
May 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29753349/can-severity-outweigh-smaller-numbers-a-deliberative-perspective-from-canada
#13
Monica Magalhaes
OBJECTIVES: To use structured deliberation to elicit and describe the values of the public in Alberta, Canada, on the question of whether the severity of a rare condition can justify it being given priority in funding over common conditions affecting larger numbers of patients, and what aspects of a condition drive this judgment. METHODS: Thematic analysis of transcripts of a group deliberative exercise carried out as part of two citizens' juries. The exercise was designed to elicit participants' conception of disease severity, and trade-offs between helping small groups with severe conditions and larger groups with less severe conditions...
May 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29753348/budgetary-impact-and-cost-drivers-of-drugs-for-rare-and-ultrarare-diseases
#14
REVIEW
Michael Schlander, Charalabos-Markos Dintsios, Afschin Gandjour
OBJECTIVES: To review recent studies reporting health care expenditures (budgetary impact) for orphan medicinal products (OMPs) in Europe and to contribute to our understanding of the cost drivers of nononcological OMPs by means of an empirical analysis in Germany. METHODS: A systematic search for relevant studies on rare diseases was conducted in PubMed and Embase (until December 2016). In addition, annual treatment costs of nononcological OMPs in Germany were analyzed with respect to five explanatory variables: total prevalence of disease, prevalence with added benefit, availability of alternative treatments for the same indication, extent/probability of treatment benefit, and evidence for a treatment effect on mortality...
May 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29753347/economic-modeling-considerations-for-rare-diseases
#15
Isobel Pearson, Ben Rothwell, Andrew Olaye, Christopher Knight
OBJECTIVES: To identify challenges that affect the feasibility and rigor of economic models in rare diseases and strategies that manufacturers have employed in health technology assessment submissions to demonstrate the value of new orphan products that have limited study data. METHODS: Targeted reviews of PubMed, the National Institute for Health and Care Excellence's (NICE's) Highly Specialised Technologies (HST), and the Scottish Medicines Consortium's (SMC's) ultra-orphan submissions were performed...
May 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29753346/clinical-outcome-assessments-use-of-normative-data-in-a-pediatric-rare-disease
#16
Dawn Phillips, Beth Leiro
Pediatric rare diseases present unique challenges in clinical trial design and in selection of clinical outcome assessments (COAs) used to support claims in medical product labeling. COAs that discriminate level of function relative to a normative sample are particularly important in the pediatric rare disease setting because the literature is often void of natural history data. Pediatric rare disease clinical trials will often include a wide age distribution. Gross and fine motor skills, communication, cognition, and independence in activities of daily living vary by age, and it may be difficult to distinguish between treatment effect and change due to developmental maturation...
May 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29753345/the-problem-of-rarity-estimation-of-prevalence-in-rare-disease
#17
Stéphane Auvin, John Irwin, Paul Abi-Aad, Alysia Battersby
BACKGROUND: From a disease's first description to its wider recognition, factors such as changes over time in diagnostic criteria, available therapies, and subsequent mortality rates may influence diagnosed prevalence of rare diseases. OBJECTIVES: To propose a novel methodology for estimating the true prevalence of rare diseases using current incidence adjusted to changing diagnostic practice over time. This article focuses on rare diseases whose diagnosis may have changed over time, and raises the hypothesis that prevalence calculated from current incidence may be higher than diagnosed prevalence, which may lag behind the current disease definition and diagnostic methods...
May 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29753344/challenges-in-research-and-health-technology-assessment-of-rare-disease-technologies-report-of-the-ispor-rare-disease-special-interest-group
#18
Sandra Nestler-Parr, Daria Korchagina, Mondher Toumi, Chris L Pashos, Christopher Blanchette, Elizabeth Molsen, Thomas Morel, Steven Simoens, Zoltán Kaló, Ruediger Gatermann, William Redekop
BACKGROUND: Successful development of new treatments for rare diseases (RDs) and their sustainable patient access require overcoming a series of challenges related to research and health technology assessment (HTA). These impediments, which may be unique to RDs or also apply to common diseases but are particularly pertinent in RDs, are diverse and interrelated. OBJECTIVE: To develop for the first time a catalog of primary impediments to RD research and HTA, and to describe the cause and effect of individual challenges...
May 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29753343/rare-diseases-addressing-the-challenges-in-diagnosis-drug-approval-and-patient-access
#19
EDITORIAL
Kati Copley-Merriman
No abstract text is available yet for this article.
May 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29680106/cost-of-tuberculosis-diagnosis-and-treatment-in-patients-with-hiv-a-systematic-literature-review
#20
REVIEW
Noemia Teixeira de Siqueira-Filha, Rosa Legood, Aracele Cavalcanti, Andreia Costa Santos
OBJECTIVES: To summarize the costs of tuberculosis (TB) diagnosis and treatment in human immunodeficiency virus (HIV)-infected patients and to assess the methodological quality of these studies. METHODS: We included cost, cost-effectiveness, and cost-utility studies that reported primary costing data, conducted worldwide and published between 1990 and August 2016. We retrieved articles in PubMed, Embase, EconLit, CINAHL plus, and LILACS databases. The quality assessment was performed using two guidelines-the Consolidated Health Economic Evaluation Reporting Standards and the Tool to Estimate Patient's Costs...
April 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
journal
journal
34615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"